New tool aims to ease burden on hong Kong's palliative caregivers
NCT ID NCT07193433
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 37 times
Summary
This study tests a tool called CSNAT-I that helps family caregivers of palliative cancer patients identify and prioritize their own support needs. 60 caregivers will be randomly assigned to receive the tool or usual care. Researchers will measure whether it reduces caregiver burden, distress, and improves quality of life, and also assess how practical it is to use in Hong Kong's healthcare system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUPPORTIVE CARE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carer Support Needs Assessment Tool Intervention (CSNAT-I)
What this could lead to
If successful, this could provide a practical way to support family caregivers, reducing their stress and improving their quality of life.
What could go wrong
This is a very small pilot study with only 60 participants, so results may not apply widely. The intervention is a conversation tool, not a drug, so benefits may be modest.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.